Amgen, Allergan join Rituxan biosimilar challenge with FDA filing

Amgen, Allergan join Rituxan biosimilar challenge with FDA filing

Source: 
Pharmaforum
snippet: 

Amgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the FDA, vying to become the third copycat version of the blockbuster drug approved in the US.